Redo retroperitoneal lymphadenectomy for germ cell tumor.
Redo retroperitoneal lymph node dissection (RPLND) for the treatment of germ cell tumors (GCTs) is an uncommonly performed procedure. We report on 9 patients who underwent redo RPLND at the University of Wisconsin (UW) between January 1988 and December 1990. Indications for redo RPLND include: residual retroperitoneal mass after initial RPLND and chemotherapy, normal alpha-fetoprotein (AFP) and beta subunit of human chorionic gonadotropin (B-HCG), otherwise negative metastatic workup, and evidence that the mass is resectable. Overall, 6 of 9 patients are alive with no evidence of disease at a mean follow-up of thirty-two months. Preoperative evaluation, histopathology, morbidity, and technical aspects of this procedure, which is a critical part of the management of GCT, are reviewed.
Waples
M J
MJ
Department of Surgery, University of Wisconsin School of Medicine, Madison.
Messing
E M
EM
D000328:Adult; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000601:surgery*; D012086:Reoperation; D012186:Retroperitoneal Neoplasms / Q000150:complications / Q000601:surgery*; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000150:complications / Q000601:surgery*